Loading…
Safer Prescribing of Controlled Substances Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
84pct
43d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Safer Prescribing of Controlled Substances Act This bill establishes a new registration requirement for a practitioner (other than a hospital, pharmacy, or veterinarian) who is licensed to dispense or conduct research with a controlled substance in schedules II, III, IV, or V of the Controlled Substances Act. Specifically, the practitioner must comply with a training requirement as a condition of obtaining or renewing their registration. The training must include information on best practices for pain management and responsible prescribing of pain medications.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2020 · fourth_quarter · Health Issues
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H. Res. 480, Acknowledging the racial disparities in diagnosing and treating mental health among youth in communities of color H.R. 1554, the Resident Education Deferred Interest Act H.R. 1763 / S. 348, the Resident Physician Shortage Reduction Act of 2019 H.R. 2734 / S. 1448, the Safer Prescribing of Controlled Substances Act H.R. 3180/ S. 1770, the RISE from Trauma Act H.R. 3239/ S. 2135, the Humanitarian Standards for Individuals in Customs and Border Protection Custody Act H.R. 3253, the Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act H.R. 3417, BETTER Act of 2019 H.R. 4194/S. 2661, the National Suicide Hotline Designation Act of 2019 H.R. 4309, the Barriers to Suicide Act H.R. 4327, the Enhancing Mental Health and Suicide Prevention Through Campus Planning Act H.R. 4861/ S. 3006, the Effective Suicide Screening and Assessment in the Emergency Department Act H.R. 4932 / S. 2741, the CONNECT for Health Act H.R. 4995, the Maternal Health Quality Improvement Act of 2019 H.R. 4996, the Helping Medicaid Offer Maternity Services Act of 2019 H.R. 5201, the Telemental Health Expansion Act of 2019 H.R. 5473, the Enhance Access to Support Essential Behavioral Health Services Act H.R.5469/ S.4388, the Pursuing Equity in Mental Health Act of 2019 H.R.5575, the Primary and Behavioral Health Care Access Act of 2020 Out of network billing legislation S. 1227, the Prescription Pricing for the People Act of 2019 S. 2443, the Investment in Tomorrow's Pediatric Health Care Workforce Act S. 824, the Excellence in Mental Health and Addiction Treatment Expansion Act S.1659, the Ensuring Childrens Access to Specialty Care Act of 2019 Title III Sec. 305 Timely Bills to Patients within the Lower Health Care Costs Act of 2019 (S. 1895) Cures 2.0 Title X Family Planning Program Administration Rule Efforts related to psychiatric bed shortages. H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, the Families First Coronavirus Response Act H.R. 4996, the Helping Medicaid Offer Maternity Services (MOMS) Act, and Senate efforts. S. 311, the Born-Alive Abortion Survivors Protection Act S. 3275, the Pain-Capable Unborn Child Protection Act H.R. 4056 and S. 2446, the Medicare Audiologist Access and Services Act of 2019 H.R. 5575, the Primary and Behavioral Health Care Access Act Telehealth provisions as related to Covid-19. H.R. 6644, the Health Care at Home Act Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 and related Medicare and Medicaid payment updates. Emergency financial relief and stability funding for 501(c)(6) tax-exempt medical and dental trade associations impacted by the pandemic H.R. 7078, the Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 (EDOT Act of 2020) H.R. 7255, the Coronavirus Health Care Worker Wellness Act of 2020 S. 3919, the Military Suicide Prevention in the 21st Century Act H.R. 7608, the Legislative Vehicle for the Fiscal 2021 Four-Bill Appropriations Package H.R. 7539, the Strengthening Behavioral Health Parity Act H.R. 4564, the Suicide Prevention Lifeline Improvement Act of 2019 H.R. 5619/ S. 3198, the Suicide Prevention Act H.R. 4585, the Campaign to Prevent Suicide Act H.R. 1646/ S. 3244, the Helping Emergency Responders Overcome (HERO) Act of 2019 H.R. 2519/ S. 1334, the Improving Mental Health Access from the Emergency Department Act of 2019 H.R. 7147, the Creating Resources to Improve Situations of Inherent Severity Act (CRISIS Act) H.R. 7159/S. 4282, the Crisis Care Improvement and Suicide Prevention Act of 2020 H.R. 7689, the Improving Data Collection for Adverse Childhood Experiences Act H.R. 8094/S. 4349, the Dr. Lorna Breen Health Care Provider Protection Act H.R. 6561/S. 4440, the Improving Social Determinants of Health Act H.R. 7511/ S. 4211, the Facilitating Reforms that Offer Necessary Telehealth in Every Rural (FRONTIER) Community Act H.R. 884 / S. 2772, the Medicare Mental Health Access Act H.R. 3935, the Protecting Patients Transportation to Care Act H.R. 4564, the Suicide Prevention Lifeline Improvement Act of 2020 S. Res. 738, Recognizing suicide as a serious public health problem and expressing support for the designation of September as National Suicide Prevention Month S. 4113, the Broadband Reform and Investment to Drive Growth in the Economy Act of 2020 (BRIDGE Act) H.R. 7859, the Strengthening Behavioral Health Supports for Schools Act S. 4421, the Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act H.R. 8141, the Strengthening Mental Health Supports for BIPOC Communities Act HR 7510, the Assimilating Health and Equity Assessments into Decision-making Act of 2020 or AHEAD Act H.R. 5469/S.4388, the Mental Health Equity Act of 2020 H.R. 7059, the Coronavirus Provider Protection Act, S. 3792, the Tele-Mental Health Improvement Act of 2020. HR 6810 to provide COBRA subsidies for unemployed and furloughed individuals during COVID H.R. 7593/S. 4103, the Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act H.R. 6645, the Mental Health Research Act H.R. 5201, the Telemental Health Expansion Act of 2019 H.R. 6561/S. 3595, the Ensuring Understanding for COVID-19 to Protect Public Health Act S. 4524, the Quit Because of COVID-19 Act S. 4486, the Achieving Thorough Transparency & Accessibility for Information Navigation (ATTAIN) on Mental Health Act H.R. 6800/H.R. 8406, the HEROES Act S. 4230, the Telehealth Expansion Act of 2020 H.R. 7391, the Protect Telehealth Access Act of 2020 H.R. 7760, To make a supplemental appropriation for the COVID-19 Telehealth Program of the Federal Communications Commission for the fiscal year ending September 30, 2020 H.R.8067, the Addressing COVID-19 Health Disparities Act H.R. 2862, the VACCINES Act of 2019 (G6 letter for internal purposes) Efforts related to Collaborative Care Model S. 3197, the Improving Access to Health Care in Rural and Underserved Areas Act H.R. 6139, the COVID-19 Health Care Worker Protection Act of 2020 H.Res. 908 (S.Res. 580) Condemning all forms of Anti-Asian Sentiment as related to COVID-19 H.R. 6585, the Equitable Data Collection and Disclosure on COVID-19 Act H.R. 7078, the EDOT Act of 2020 HR 7077, the Community Solutions for COVID-19 Act H.R. 7780, the Virtual Community Support Act of 2020 H. R. 8016, the Peer Assisted Relief Through Empathetic Resources and Supports (PARTNERS) Act H. R. 8206, the Promoting Effective and Empowering Recovery Services in Medicare Act of 2020 (PEERS Medicare Act of 2020) 2021 Centers for Medicare and Medicaid Services (CMS), Medicare Physician Fee Schedule (MPFS) Final Rule, E/M (H.R. 8702; H.R. 8505; S. 4932) H.R. 9035, the Permanency for Audio Only Telehealth Act H.R. 7663, Protecting Access to Post-COVID-19 Telehealth Act of 2020 H.R. 8283/S. 4421 TREAT Act H.R. 2482/S. 2074 Mainstreaming Addiction Treatment Act of 2019 Misuse of race data within clinical algorithms.
Client expense: $238,000 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of the Vice President of the United States, SENATE, Veterans Affairs, Dept of (VA), White House Office
2020 · third_quarter · Health Issues
H. Res. 480, Acknowledging the racial disparities in diagnosing and treating mental health among youth in communities of color H.R. 1109, the Mental Health Services for Students Act of 2019 H.R. 1554, the Resident Education Deferred Interest Act H.R. 1763 / S. 348, the Resident Physician Shortage Reduction Act of 2019 H.R. 2279/ S. 2546, the Safe Step Act H.R. 2482/ S. 2074, the Mainstreaming Addiction Treatment Act of 2019 H.R. 2734 / S. 1448, the Safer Prescribing of Controlled Substances Act H.R. 3180/ S. 1770, the RISE from Trauma Act H.R. 3239/ S. 2135, the Humanitarian Standards for Individuals in Customs and Border Protection Custody Act H.R. 3253, the Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act H.R. 3414/ S. 2892, the Opioid Workforce Act H.R. 3417, BETTER Act of 2019 H.R. 4194/S. 2661, the National Suicide Hotline Designation Act of 2019 H.R. 4309, the Barriers to Suicide Act H.R. 4327, the Enhancing Mental Health and Suicide Prevention Through Campus Planning Act H.R. 4861/ S. 3006, the Effective Suicide Screening and Assessment in the Emergency Department Act H.R. 4932 / S. 2741, the CONNECT for Health Act H.R. 4995, the Maternal Health Quality Improvement Act of 2019 H.R. 4996, the Helping Medicaid Offer Maternity Services Act of 2019 H.R. 5, the Equality Act H.R. 5201, the Telemental Health Expansion Act of 2019 H.R. 5473, the Enhance Access to Support Essential Behavioral Health Services Act H.R.5469, the Pursuing Equity in Mental Health Act of 2019 H.R.5575, the Primary and Behavioral Health Care Access Act of 2020 Out of network billing legislation S. 1227, the Prescription Pricing for the People Act of 2019 S. 2443, the Investment in Tomorrow's Pediatric Health Care Workforce Act S. 824, the Excellence in Mental Health and Addiction Treatment Expansion Act S.1659, the Ensuring Childrens Access to Specialty Care Act of 2019 Title III Sec. 305 Timely Bills to Patients within the Lower Health Care Costs Act of 2019 (S. 1895) Cures 2.0 Title X Family Planning Program Administration Rule Efforts related to psychiatric bed shortages. H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, the Families First Coronavirus Response Act H.R. 748, the Coronavirus Aid, Relief and Economic Security (CARES) Act H.R. 2895/ S. 948, the Conrad State 30 and Physician Access Reauthorization Act H.R. 4996, the Helping Medicaid Offer Maternity Services (MOMS) Act, and Senate efforts. S. 311, the Born-Alive Abortion Survivors Protection Act S. 3275, the Pain-Capable Unborn Child Protection Act H.R. 4056 and S. 2446, the Medicare Audiologist Access and Services Act of 2019 H.R. 5575, the Primary and Behavioral Health Care Access Act Telehealth provisions as related to Covid-19. H.R. 6644, the Health Care at Home Act H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including the Payroll Protection Program (PPP), the Public Health and Social Services Emergency Fund, and more. Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 and related Medicare and Medicaid payment updates. Emergency financial relief and stability funding for 501(c)(6) tax-exempt medical and dental trade associations impacted by the pandemic H.R. 7078, the Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 (EDOT Act of 2020) H.R. 7255, the Coronavirus Health Care Worker Wellness Act of 2020 S. 3919, the Military Suicide Prevention in the 21st Century Act H.R. 7608, the Legislative Vehicle for the Fiscal 2021 Four-Bill Appropriations Package Recommendations on confidential mental health records sharing. H.R. 7539, the Strengthening Behavioral Health Parity Act H.R. 4564, the Suicide Prevention Lifeline Improvement Act of 2019 H.R. 5619, the Suicide Prevention Act H.R. 4585, the Campaign to Prevent Suicide Act H.R. 1646, the Helping Emergency Responders Overcome (HERO) Act of 2019 H.R. 2519, the Improving Mental Health Access from the Emergency Department Act of 2019 H.R. 7147, the Creating Resources to Improve Situations of Inherent Severity Act (CRISIS Act) H.R. 7159/S. 4282, the Crisis Care Improvement and Suicide Prevention Act of 2020 21st Century Cures Act, RE: Opioid State Targeted Response Grants H.R. 7689, the Improving Data Collection for Adverse Childhood Experiences Act H.R. 8094/S. 4349, the Dr. Lorna Breen Health Care Provider Protection Act H.R. 6561/S. 4440, the Improving Social Determinants of Health Act H.R. 7511/ S. 4211, the Facilitating Reforms that Offer Necessary Telehealth in Every Rural (FRONTIER) Community Act H.R. 884 / S. 2772, the Medicare Mental Health Access Act H.R. 1763, the Resident Physician Shortage Reduction Act of 2019 S. 2661, the National Suicide Hotline Designation Act of 2020 (Sen. Gardner - Energy and Commerce) H.R. 3935, the Protecting Patients Transportation to Care Act H.R. 4564, the Suicide Prevention Lifeline Improvement Act of 2020 S. Res. 738, Recognizing suicide as a serious public health problem and expressing support for the designation of September as National Suicide Prevention Month S. 4113, the Broadband Reform and Investment to Drive Growth in the Economy Act of 2020 (BRIDGE Act) H.R. 7859, the Strengthening Behavioral Health Supports for Schools Act S. 4421, the Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act H.R. 8141, the Strengthening Mental Health Supports for BIPOC Communities Act HR 7510, the Assimilating Health and Equity Assessments into Decision-making Act of 2020 or AHEAD Act H.R. 5469/S.4388, the Mental Health Equity Act of 2020 H.R. 7059, the Coronavirus Provider Protection Act, S. 3792, the Tele-Mental Health Improvement Act of 2020. HR 6810 to provide COBRA subsidies for unemployed and furloughed individuals during COVID H.R. 7593/S. 4103, the Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act H.R. 6645, the Mental Health Research Act H.R. 7539, the Strengthening Behavioral Health Parity Act H.R. 5201, the Telemental Health Expansion Act of 2019 H.R. 6561/S. 3595, the Ensuring Understanding for COVID-19 to Protect Public Health Act S. 4524, the Quit Because of COVID-19 Act S. 4486, the Achieving Thorough Transparency & Accessibility for Information Navigation (ATTAIN) on Mental Health Act H.R. 6800/H.R. 8406, the HEROES Act H.R. 7663, the Protecting Access to Post-COVID-19 Telehealth Act of 2020 S. 4230, the Telehealth Expansion Act of 2020 H.R. 7391, the Protect Telehealth Access Act of 2020 H.R. 7760, To make a supplemental appropriation for the COVID-19 Telehealth Program of the Federal Communications Commission for the fiscal year ending September 30, 2020 H.R.8067, the Addressing COVID-19 Health Disparities Act H.R. 2862, the VACCINES Act of 2019 (G6 letter for internal purposes) Efforts related to Collaborative Care Model S. 3197, the Improving Access to Health Care in Rural and Underserved Areas Act H.R. 6139, the COVID-19 Health Care Worker Protection Act of 2020 H.Res. 908 (S.Res. 580) Condemning all forms of Anti-Asian Sentiment as related to COVID-19 H.R. 6585, the Equitable Data Collection and Disclosure on COVID-19 Act H.R. 7078, the EDOT Act of 2020 HR 7077, the Community Solutions for COVID-19 Act S. 4441, the Crisis Assistance Helping Out On The Streets (CAHOOTS) Act
Client expense: $144,000 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of the Vice President of the United States, SENATE, Veterans Affairs, Dept of (VA), White House Office
2020 · second_quarter · Health Issues
H. Res. 480, Acknowledging the racial disparities in diagnosing and treating mental health among youth in communities of color H.R. 1109, the Mental Health Services for Students Act of 2019 H.R. 1554, the Resident Education Deferred Interest Act H.R. 1763 / S. 348, the Resident Physician Shortage Reduction Act of 2019 H.R. 2062 / S. 1012 (42 CFR Part 2) H.R. 2279/ S. 2546, the Safe Step Act H.R. 2482/ S. 2074, the Mainstreaming Addiction Treatment Act of 2019 H.R. 2734 / S. 1448, the Safer Prescribing of Controlled Substances Act H.R. 2862, the VACCINES Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 3180/ S. 1770, the RISE from Trauma Act H.R. 3239/ S. 2135, the Humanitarian Standards for Individuals in Customs and Border Protection Custody Act H.R. 3253, the Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act H.R. 3414/ S. 2892, the Opioid Workforce Act H.R. 3417, BETTER Act of 2019 H.R. 4194, S. 2661, the National Suicide Hotline Designation Act of 2019 H.R. 4309, the Barriers to Suicide Act H.R. 4327, the Enhancing Mental Health and Suicide Prevention Through Campus Planning Act H.R. 4861/ S. 3006, the Effective Suicide Screening and Assessment in the Emergency Department Act H.R. 4932 / S. 2741, the CONNECT for Health Act H.R. 4995, the Maternal Health Quality Improvement Act of 2019 H.R. 4996, the Helping Medicaid Offer Maternity Services Act of 2019 H.R. 5, the Equality Act H.R. 5201, the Telemental Health Expansion Act of 2019 H.R. 5473, the Enhance Access to Support Essential Behavioral Health Services Act H.R.5469, the Pursuing Equity in Mental Health Act of 2019 H.R.5575, the Primary and Behavioral Health Care Access Act of 2020 Out of network billing legislation S. 1227, the Prescription Pricing for the People Act of 2019 S. 2443, the Investment in Tomorrow's Pediatric Health Care Workforce Act S. 824, the Excellence in Mental Health and Addiction Treatment Expansion Act S.1659, the Ensuring Childrens Access to Specialty Care Act of 2019 Title III Sec. 305 Timely Bills to Patients within the Lower Health Care Costs Act of 2019 (S. 1895) Cures 2.0 Suggestions related to addressing mental health in rural communities. Title X Family Planning Program Administration Rule Efforts related to psychiatric bed shortages. H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, the Families First Coronavirus Response Act H.R. 748, the Coronavirus Aid, Relief and Economic Security (CARES) Act H.R. 2895, S. 948, the Conrad State 30 and Physician Access Reauthorization Act H.R. 4996, the Helping Medicaid Offer Maternity Services (MOMS) Act, and Senate efforts. S. 311, the Born-Alive Abortion Survivors Protection Act S. 3275, the Pain-Capable Unborn Child Protection Act H.R. 4056 and S. 2446, the Medicare Audiologist Access and Services Act of 2019 H.R. 5575, the Primary and Behavioral Health Care Access Act Telehealth provisions as related to Covid-19. H.R. 6644, the Health Care at Home Act H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including the Payroll Protection Program (PPP), the Public Health and Social Services Emergency Fund, the provider fund (for MH funding), and more. Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 and related Medicare and Medicaid payment updates. Emergency financial relief and stability funding for 501(c)(6) tax-exempt medical and dental trade associations impacted by the pandemic H.R.7078 , the Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 (EDOT Act of 2020) H.R. 7255, the Coronavirus Health Care Worker Wellness Act of 2020 S.3919, Military Suicide Prevention in the 21st Century Act H.R. 7608, Legislative Vehicle for the Fiscal 2021 Four-Bill Appropriations Package H.R. 6788/S. 3599, Healthcare Workforce Resilience Act Recommendations on confidential mental health records sharing. H.R. 4564, the Suicide Prevention Lifeline Improvement Act of 2019 H.R. 5619, the Suicide Prevention Act H.R. 4585, the Campaign to Prevent Suicide Act H.R. 1646, the Helping Emergency Responders Overcome (HERO) Act of 2019 H.R.884/S. 2772, the Medicare Mental Health Access Act H.R. 2519, the Improving Mental Health Access from the Emergency Department Act of 2019 H.R. 7147, the Creating Resources to Improve Situations of Inherent Severity Act (CRISIS Act) H.R. 7159, the Crisis Care Improvement and Suicide Prevention Act of 2020 21st Century Cures Act, RE: Opioid State Targeted Response Grants S.4088, the Ensuring Access to Primary Care for Women & Children Act H.R. 6159, the KIDS Access to Primary Care Act S. 3741, the Health Care at Home Act S. 3792, the Tele-mental Health Improvement Act H.R. 6697, the Local Chamber, Tourism, and 501(c)(6) Protection Act
Client expense: $162,000 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of the Vice President of the United States, SENATE, Veterans Affairs, Dept of (VA), White House Office
2020 · first_quarter · Health Issues
H. Res. 480, Acknowledging the racial disparities in diagnosing and treating mental health among youth in communities of color H.R. 1109, the Mental Health Services for Students Act of 2019 H.R. 1554, the Resident Education Deferred Interest Act H.R. 1763 / S. 348, the Resident Physician Shortage Reduction Act of 2019 H.R. 2062 / S. 1012 (42 CFR Part 2) and S. 3374, the Protecting Jessica Grubb's Legacy Act H.R. 2279/ S. 2546, the Safe Step Act H.R. 2482/ S. 2074, the Mainstreaming Addiction Treatment Act of 2019 H.R. 2734 / S. 1448, the Safer Prescribing of Controlled Substances Act H.R. 2862, the VACCINES Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 3180/ S. 1770, the RISE from Trauma Act H.R. 3239/ S. 2135, the Humanitarian Standards for Individuals in Customs and Border Protection Custody Act H.R. 3253, the Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act H.R. 3414/ S. 2892, the Opioid Workforce Act H.R. 3417, BETTER Act of 2019 H.R. 4194, S. 2661, the National Suicide Hotline Designation Act of 2019 H.R. 4309, the Barriers to Suicide Act H.R. 4327, the Enhancing Mental Health and Suicide Prevention Through Campus Planning Act H.R. 4861/ S. 3006, the Effective Suicide Screening and Assessment in the Emergency Department Act H.R. 4932 / S. 2741, the CONNECT for Health Act H.R. 4995, the Maternal Health Quality Improvement Act of 2019 H.R. 4996, the Helping Medicaid Offer Maternity Services Act of 2019 H.R. 5, the Equality Act H.R. 5201, the Telemental Health Expansion Act of 2019 H.R. 5473, the Enhance Access to Support Essential Behavioral Health Services Act H.R.5469, the Pursuing Equity in Mental Health Act of 2019 H.R.5575, the Primary and Behavioral Health Care Access Act of 2020 Out of network billing legislation S. 1227, the Prescription Pricing for the People Act of 2019 S. 2443, the Investment in Tomorrow's Pediatric Health Care Workforce Act S. 824, the Excellence in Mental Health and Addiction Treatment Expansion Act S.1659, the Ensuring Childrens Access to Specialty Care Act of 2019 Title III Sec. 305 Timely Bills to Patients within the Lower Health Care Costs Act of 2019 (S. 1895) Cures 2.0 Suggestions related to addressing mental health in rural communities. Title X Family Planning Program Administration Rule Efforts related to psychiatric bed shortages. H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, the Families First Coronavirus Response Act H.R. 748, the Coronavirus Aid, Relief and Economic Security (CARES) Act H.R. 2895, S. 948, the Conrad State 30 and Physician Access Reauthorization Act H.R. 4996, the Helping Medicaid Offer Maternity Services (MOMS) Act, and Senate efforts. S. 311, the Born-Alive Abortion Survivors Protection Act S. 3275, the Pain-Capable Unborn Child Protection Act H.R. 4056 and S. 2446, the Medicare Audiologist Access and Services Act of 2019 H.R. 5575, the Primary and Behavioral Health Care Access Act H.R. 6143, the MOMS Matter Act H.R. 1309, the Workplace Violence Prevention for Health Care and Social Service Workers Act
Client expense: $210,000 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of the Vice President of the United States, President of the U.S., SENATE, U.S. Immigration & Customs Enforcement (ICE), Veterans Affairs, Dept of (VA), White House Office
2019 · fourth_quarter · Health Issues
H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1922: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4244: MAGIC Act - Provisions related to FDA approval pathways H.R. 4439: Creating Hope Reauthorization Act - Provisions related to rare disease priority review vouchers H.R. 4538: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B prescription drug exclusions H.R. 4633: Investing in Safety and Innovation Act of 2019 - Provisions related to FDA programs reauthorization H.R. 4640: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 - Provisions related to prescription drug pricing and negotiation H.R. 4667: Biomedical Innovation Expansion Act of 2019 - Provisions related to NIH programs reauthorization H.R. 4710: Pharmaceutical Independence Long-Term Readiness Reform Act - Provisions related to the supply chain H.R. 4711: No Tax Breaks for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 4866: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019 - Provisions related to designation of universities as centers of excellence supporting manufacturing H.R. 4963: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2019 - Provisions related to synthetic analogues H.R. 5031: Medical Innovation Act of 2019 - Provisions related to prescription drug manufacturer taxation and supplemental fees H.R. 5198: Patients' Right to Know Their Medication Act of 2019 - Provisions related to prescription drug labeling H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5304: PBM Transparency in Prescription Drug Costs Act - Provisions related to prescription drug pricing transparency H.R. 5381: International Pharmaceutical Transparency Act of 2019 - Provisions related to prescription drug labeling H.R. 5442: To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes. - Provisions related to prescription drug pricing and transparency H.R. 5497: Conditional Approval Act - Provisions related to approval pathway S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1250: American Cures Act - Provisions related to pharmaceutical research and development S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49) Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45) Monograph Reform, HSA/FSAs S 2740 - Over-the-Counter Monograph Safety S1872/HR5076, Protecting Seniors Through Immunization Act S1654/HR1973, Vaccine Access Improvement Act
Client expense: $700,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2019 · fourth_quarter · Health Issues
H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1922: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2732: Lessening Addiction By Enhancing Labeling Opioids Act of 2019 - Provisions related to labeling of prescription drugs H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4010: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug access programs H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4439: Creating Hope Reauthorization Act - Provisions related to rare disease priority review vouchers H.R. 4538: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B prescription drug exclusions H.R. 4633: Investing in Safety and Innovation Act of 2019 - Provisions related to FDA programs reauthorization H.R. 4640: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 - Provisions related to prescription drug pricing and negotiation H.R. 4667: Biomedical Innovation Expansion Act of 2019 - Provisions related to NIH programs reauthorization H.R. 4710: Pharmaceutical Independence Long-Term Readiness Reform Act - Provisions related to the supply chain H.R. 4711: No Tax Breaks for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 4814: Suspicious Order Identification Act of 2019 - Provisions related to reporting on distribution of controlled substances H.R. 4906: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency H.R. 4963: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2019 - Provisions related to synthetic analogues H.R. 5031: Medical Innovation Act of 2019 - Provisions related to prescription drug manufacturer taxation and supplemental fees H.R. 5198: Patients' Right to Know Their Medication Act of 2019 - Provisions related to prescription drug labeling H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5304: PBM Transparency in Prescription Drug Costs Act - Provisions related to prescription drug pricing transparency H.R. 5381: International Pharmaceutical Transparency Act of 2019 - Provisions related to prescription drug labeling H.R. 5382: To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices - Provisions related to prescription drug pricing H.R. 5442: To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes - Provisions related to prescription drug pricing and transparency H.R. 5497: Conditional Approval Act - Provisions related to approval pathway S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1250: American Cures Act - Provisions related to pharmaceutical research and development S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2103: Affordable Insulin Approvals Now Act - Provisions related to FDA prescription drug approvals S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2199: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49) Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45)
2019 · fourth_quarter · Alcohol and Drug Abuse
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.
2019 · fourth_quarter · Insurance
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.
2019 · fourth_quarter · Budget/Appropriations
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.
2019 · fourth_quarter · Medicare/Medicaid
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.
2019 · fourth_quarter · Health Issues
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.
2019 · fourth_quarter · Medical/Disease Research/Clinical Labs
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported HR 4974: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products Submitted comments on amendments to regulations under the Federal anti-kickback statute (AKS). The proposed amendments would modify and add new safe harbors under the statute and exceptions to the beneficiary inducements civil monetary penalty definition of remuneration to foster arrangements that would promote care coordination and advance the delivery of value-based care while also protecting patients and taxpayer dollars against harms caused by fraud and abuse. Supported H.Res. 714: Recognizing addiction as a disease and supporting efforts to prevent, treat, and destigmatize substance use disorder and addiction. Submitted a response to a request for information (RFI) regarding substance use disorder (SUD) treatment by Representatives Greg Walden, Michael Burgess, and Brett Guthrie, Republican leaders of the House Committee on Energy and Commerce. The RFI focused on challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment. Provided comments to ONDCP regarding next National Drug Control Strategy per invitation, focusing on addiction treatment workforce, setting standards, monitoring program effectiveness, coverage for addiction treatment services.
2019 · fourth_quarter · Medicare/Medicaid
Prescription Drugs S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products. H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Safety of imported drug components - no specific bill Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Comprehensive gun control legislation Medicare/Medicaid S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections Changes to MACRA - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Publications Open access to information based on publicly funded research Regulations Executive Order entitled, "Protecting and Improving Medicare for our Nation's Seniors." CMS- Proposed changes to Medicaid Funding
2019 · fourth_quarter · Health Issues
Prescription Drugs S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products. H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Safety of imported drug components - no specific bill Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Comprehensive gun control legislation Medicare/Medicaid S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections Changes to MACRA - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Publications Open access to information based on publicly funded research Regulations Executive Order entitled, "Protecting and Improving Medicare for our Nation's Seniors." CMS- Proposed changes to Medicaid Funding
2019 · fourth_quarter · Alcohol and Drug Abuse
Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · fourth_quarter · Health Issues
H. Res. 480, Acknowledging the racial disparities in diagnosing and treating mental health among youth in communities of color H.R. 1109, the Mental Health Services for Students Act of 2019 H.R. 1554, the Resident Education Deferred Interest Act H.R. 1763 / S. 348, the Resident Physician Shortage Reduction Act of 2019 H.R. 2062 / S. 1012 (42 CFR Part 2) H.R. 2279/ S. 2546, the Safe Step Act H.R. 2482/ S. 2074, the Mainstreaming Addiction Treatment Act of 2019 H.R. 2734 / S. 1448, the Safer Prescribing of Controlled Substances Act H.R. 2862, the VACCINES Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 3180/ S. 1770, the RISE from Trauma Act H.R. 3239/ S. 2135, the Humanitarian Standards for Individuals in Customs and Border Protection Custody Act H.R. 3253, the Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act H.R. 3414/ S. 2892, the Opioid Workforce Act H.R. 3417, BETTER Act of 2019 H.R. 4194, S. 2661, the National Suicide Hotline Designation Act of 2019 H.R. 4309, the Barriers to Suicide Act H.R. 4327, the Enhancing Mental Health and Suicide Prevention Through Campus Planning Act H.R. 4861/ S. 3006, the Effective Suicide Screening and Assessment in the Emergency Department Act H.R. 4932 / S. 2741, the CONNECT for Health Act H.R. 4995, the Maternal Health Quality Improvement Act of 2019 H.R. 4996, the Helping Medicaid Offer Maternity Services Act of 2019 H.R. 5, the Equality Act H.R. 5201, the Telemental Health Expansion Act of 2019 H.R. 5473, the Enhance Access to Support Essential Behavioral Health Services Act H.R.5469, the Pursuing Equity in Mental Health Act of 2019 H.R.5575, the Primary and Behavioral Health Care Access Act of 2020 Out of network billing legislation S. 1227, the Prescription Pricing for the People Act of 2019 S. 2443, the Investment in Tomorrow's Pediatric Health Care Workforce Act S. 824, the Excellence in Mental Health and Addiction Treatment Expansion Act S.1659, the Ensuring Childrens Access to Specialty Care Act of 2019 Title III Sec. 305 Timely Bills to Patients within the Lower Health Care Costs Act of 2019 (S. 1895) Cures 2.0 Guidance related to flavored cigarette products. Suggestions related to addressing mental health in rural communities. Title X Family Planning Program Administration Rule Efforts related to psychiatric bed shortages.
2019 · third_quarter · Health Issues
H.R.1763 / S. 348, the Resident Physician Shortage Reduction Act of 2019 H.R. 2062 / S. 1012 (42 CFR Part 2) H.R. 1585, the Violence Against Women Reauthorization Act H.R. 5, the Equality Act H.R. 1109, the Mental Health Services for Students Act of 2019 S. 824, the Excellence in Mental Health and Addiction Treatment Expansion Act H.R. 2300 Eliminating Debtor's Prison for Kids Act of 2019 Activity to promote evidence-based trauma-informed care Out of network billing legislation H.R. 2569/S. 1365, the CARE Act H.R. 3414, the Opioid Workforce Act S. 1895, the Lower Health Care Costs Act H.R. 3496, the CREATE Opportunities Act S. 1227, the Prescription Pricing for the People Act of 2019 H.R. 2874 / S. 1576, the Behavioral Health Coverage Transparency Act S.1659, the Ensuring Childrens Access to Specialty Care Act of 2019 H.R. 3253, the Empowering Beneficiaries, Ensuring Access, and Strengthening Accountability Act H.R. 1554, the Resident Education Deferred Interest Act H.R. 3239, the Humanitarian Standards for Individuals in Customs and Border Protection Custody Act H.R. 3180/ S. 1770, the RISE from Trauma Act H.R. 2862, the VACCINES Act of 2019 H.R. 4309, the Barriers to Suicide Act H.R. 2569/S. 1365, the Comprehensive Addiction Resources Emergency (CARE) Act H.R. 2279, the Safe Step Act H.R. 4327, the Enhancing Mental Health and Suicide Prevention Through Campus Planning Act H.R. 3735, the Law Enforcement Suicide Data Collection Act H.R. 3417, BETTER Act of 2019 H. Res. 337, Expressing support for the designation of May 2019 as "Mental Health Awareness Month H. Res. 587, Recognizing LGBTQ+ suicide as a public health problem and expressing support for the designation of September as "National Suicide Prevention Month" H. Res. 480, Acknowledging the racial disparities in diagnosing and treating mental health among youth in communities of color S. 1227, the Prescription Pricing for the People Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 2734 / S. 1448, the Safer Prescribing of Controlled Substances Act H.R. 2482/ S. 2074, the Mainstreaming Addiction Treatment Act of 2019 Title X Family Planning Program Administration Rule Maternal mortality legislation
2019 · third_quarter · Health Issues
H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1603: Alan Reinstein Ban Asbestos Now Act of 2019 - Provisions related to use of asbestos in manufacturing H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2401: American Cures Act - Provisions related to pharmaceutical research and development H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3443: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 - Provisions related to FDA over-the-counter drug approvals H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4538: To amend title III of the Public Health Service Act to limit the orphan drug exclusion under the drug discount program under section 340B of such title. - Provisions related to 340B prescription drug exclusions S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 844: Short on Competition Act - Provisions related to generic prescription drug approvals and importation S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency S. 2103: Affordable Insulin Approvals Now Act - Provisions related to FDA prescription drug approvals S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2199: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency S. 2387: We Protect American Investment in Drugs Act - Provisions related to prescription drug pricing Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)
2019 · third_quarter · Alcohol and Drug Abuse
Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Health Issues
Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Mental Health S. 1576, H.R. 2874 - Behavioral Health Coverage Transparency Act Proposed Changes to 42 CFR, Part 2 - no specific bill Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Regulatory Issues Docket ID HHS-OCR-2019-0007, RIN 0945-AA11, Nondiscrimination in Health and Health Education Programs or Activities File Code CMS-1715-P; Medicare Program: CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicaid Promoting Interoperability Program Requirements for Eligible Professionals; Establishment of an Ambulance Data Collection System; Updates to the Quality Payment Program; Medicare Enrollment of Opioid Treatment Programs and Enhancements to Provider Enrollment Regulations Concerning Improper Prescribing and Patient Harm; and Amendments to Physician Self-Referral Law Advisory Opinion Regulations 42 CFR Part 2 [SAMHSA-4162-20]RIN 0930-AA32 Confidentiality of Substance Use Disorder Patient Records 42 CFR Part 2 [SAMHSA-4162-20]RIN 0930-AA30 Confidentiality of Substance Use Disorder Patient Records: Proposed Changes to 42 CFR Part 2
2019 · third_quarter · Medicare/Medicaid
Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Mental Health S. 1576, H.R. 2874 - Behavioral Health Coverage Transparency Act Proposed Changes to 42 CFR, Part 2 - no specific bill Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Regulatory Issues Docket ID HHS-OCR-2019-0007, RIN 0945-AA11, Nondiscrimination in Health and Health Education Programs or Activities File Code CMS-1715-P; Medicare Program: CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicaid Promoting Interoperability Program Requirements for Eligible Professionals; Establishment of an Ambulance Data Collection System; Updates to the Quality Payment Program; Medicare Enrollment of Opioid Treatment Programs and Enhancements to Provider Enrollment Regulations Concerning Improper Prescribing and Patient Harm; and Amendments to Physician Self-Referral Law Advisory Opinion Regulations 42 CFR Part 2 [SAMHSA-4162-20]RIN 0930-AA32 Confidentiality of Substance Use Disorder Patient Records 42 CFR Part 2 [SAMHSA-4162-20]RIN 0930-AA30 Confidentiality of Substance Use Disorder Patient Records: Proposed Changes to 42 CFR Part 2
2019 · third_quarter · Alcohol and Drug Abuse
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products
2019 · third_quarter · Medical/Disease Research/Clinical Labs
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products
2019 · third_quarter · Health Issues
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products
2019 · third_quarter · Budget/Appropriations
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products
2019 · third_quarter · Insurance
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Supported the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Submitted a letter in response to a request for comments from the Food and Drug Administration regarding data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. ASAMs letter stressed the importance of conducting additional research on cannabis. Supported the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. The bill would ensure that a supply of cannabis is continuously available to researchers, streamline various cannabis related application processes that run through the Department of Justice, and require the Department of Health and Human Services to conduct a review of existing research on cannabis. Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), introduced by Senator Dick Durbin and Senator Lisa Murkowski (S. 655) and Representative Diana DeGette and Representative Jamie Raskin (H.R. 1498). The bill would prohibit flavors in e-cigarettes unless the manufacturer demonstrates that a flavor will help with smoking cessation, not increase youth initiation, and not increase the risk of harm to the user. It furthermore prohibits use of flavors in other non-cigarette tobacco products, such as cigars and smokeless tobacco. Opposed the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would prohibit FDA from promulgating any public health protections related to what the cigar industry calls traditional large and premium cigars. Even the most basic Food and Drug Administration (FDA) requirements like ingredient disclosure and warning labels as well as enforcement of youth access laws would not apply to these products. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT. Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products
2019 · third_quarter · Medicare/Medicaid
Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements. Discussions/comments regarding FY20 Medicare Physician Fee Schedule, particularly around OTP payment bundle and OUD demonstration payment codes Advocated for filing of the Medication Access and Training Expansion Act which would require every DEA controlled substance prescriber to satisfy an addiction medicine education requirement Issued a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Expanding Findings for Federal Opioid Research and Treatment (EFFORT) Act, sponsored by Representative Jennifer Wexton (D-VA) and Representative Jim Baird (R-IN). The bill would direct the National Science Foundation to support research on opioid use disorder. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Provided comments to SAMHSA's issuance of notices of proposed rulemaking (NPRM), Coordinating Care and Information Sharing in the Treatment of Substance Use Disorders, which would, among other things, modify and modernize 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records. The changes would strengthen the ability of healthcare providers to coordinate care for patients suffering from substance use disorder. Replied to the Request for Information: Ensuring Patient Access and Effective Drug Enforcement. In its comments, ASAM urged the DEA to investigate whether some of its policies were unintentionally decreasing access to buprenorphine. The letter also discussed opportunities for improved education of the medical community, and possible enhancements to state PDMPs. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Submitted comments on the 2020 Medicare Physician Fee Schedule Proposed Rule. In its comments, ASAM applauded the introduction of two bundled payment structures, one for outpatient treatment of OUD and one for OTPs. However, it also noted that the proposed reimbursement rates were significantly lower than necessary to expand access to MAT.
2019 · second_quarter · Health Issues
H.R. 269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 - Provisions related to reauthorization of the Pandemic and All-Hazards Preparedness Act H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1603: Alan Reinstein Ban Asbestos Now Act of 2019 - Provisions related to use of asbestos in manufacturing H.R. 1730: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing H.R. 2011: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products H.R. 2020: STEER Act - Provisions related to encapsulating & tableting machine registration H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2296: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2584: To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings - Provisions related to CBO scoring of preventive health savings H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: To amend title XI of the Social Security Act to require that direct-to-consumer television advertisements for prescription drugs and biological products include the list price of such drugs and products, and for other purposes - Provisions related to direct-to-consumer prescription drug advertising H.R. 3379: Price Relief, Innovation, and Competition for Essential Drugs or PRICED Act - Provisions related to exclusivity H.R. 3408: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3415: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3443: To clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes - Provisions related to FDA over-the-counter drug approvals S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 419: Protecting Americans from Dangerous Opioids Act - Provisions related to FDA drug approvals S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes S. 474: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 741: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing S. 989: STEER Act - Provisions related to encapsulating & tableting machine registration S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Reauthorization of the Pandemic and All-Hazards Preparedness Act Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)
2019 · second_quarter · Health Issues
H.R. 269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 - Provisions related to reauthorization of the Pandemic and All-Hazards Preparedness Act H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1603: Alan Reinstein Ban Asbestos Now Act of 2019 - Provisions related to use of asbestos in manufacturing H.R. 1730: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing H.R. 1922: Restoring Access to Medicine Act H.R. 2011: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products H.R. 2020: STEER Act - Provisions related to encapsulating & tableting machine registration H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2296: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2584: To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings - Provisions related to CBO scoring of preventive health savings H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: To amend title XI of the Social Security Act to require that direct-to-consumer television advertisements for prescription drugs and biological products include the list price of such drugs and products, and for other purposes - Provisions related to direct-to-consumer prescription drug advertising H.R. 3379: Price Relief, Innovation, and Competition for Essential Drugs or PRICED Act - Provisions related to exclusivity H.R. 3408: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3415: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3443: To clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes - Provisions related to FDA over-the-counter drug approvals S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S.12: Health Savings Account of 2019 S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S.182: Protecting Seniors through Immunization Act S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes S. 474: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 741: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing S. 989: STEER Act - Provisions related to encapsulating & tableting machine registration S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S.1654/H.R. 1973: Vaccine Access Improvement Act S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues Prescription drug take back and secure disposal policy issues Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Reauthorization of the Pandemic and All-Hazards Preparedness Act Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)
2019 · second_quarter · Health Issues
H.R. 269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 - Provisions related to reauthorization of the Pandemic and All-Hazards Preparedness Act H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1603: Alan Reinstein Ban Asbestos Now Act of 2019 - Provisions related to use of asbestos in manufacturing H.R. 1730: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing H.R. 2011: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products H.R. 2020: STEER Act - Provisions related to encapsulating & tableting machine registration H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2296: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2584: To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings - Provisions related to CBO scoring of preventive health savings H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: To amend title XI of the Social Security Act to require that direct-to-consumer television advertisements for prescription drugs and biological products include the list price of such drugs and products, and for other purposes - Provisions related to direct-to-consumer prescription drug advertising H.R. 3379: Price Relief, Innovation, and Competition for Essential Drugs or PRICED Act - Provisions related to exclusivity H.R. 3408: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3415: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3443: To clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes - Provisions related to FDA over-the-counter drug approvals S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 419: Protecting Americans from Dangerous Opioids Act - Provisions related to FDA drug approvals S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes S. 474: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 741: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing S. 989: STEER Act - Provisions related to encapsulating & tableting machine registration S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Reauthorization of the Pandemic and All-Hazards Preparedness Act Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)
2019 · second_quarter · Budget/Appropriations
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
2019 · second_quarter · Health Issues
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
2019 · second_quarter · Medicare/Medicaid
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
2019 · second_quarter · Medical/Disease Research/Clinical Labs
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
2019 · second_quarter · Alcohol and Drug Abuse
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
2019 · second_quarter · Alcohol and Drug Abuse
Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · second_quarter · Medicare/Medicaid
Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Surprise Billing S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R.2000 - Medicare-X Choice Act of 2019 ACA Protections H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Mental Health S. 1576, H.R. 2874 - Behavioral Health Coverage Transparency Act Regulatory Issues 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program. (RIN: 0955-AA01 CFR:45 CFR Parts 170 and 171; Federal Register Number:2019-02224) CMS - Problems with prior authorization
2019 · second_quarter · Health Issues
Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Surprise Billing S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R.2000 - Medicare-X Choice Act of 2019 ACA Protections H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Mental Health S. 1576, H.R. 2874 - Behavioral Health Coverage Transparency Act Regulatory Issues 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program. (RIN: 0955-AA01 CFR:45 CFR Parts 170 and 171; Federal Register Number:2019-02224) CMS - Problems with prior authorization
| Democratic |
| VA |
| Jahana Hayes | Democratic | CT |
| Mary Gay Scanlon | Democratic | PA |
| Paul Tonko | Democratic | NY |
| Yvette D. Clarke | Democratic | NY |
Client expense: $6,450,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $70,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
Client expense: $70,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
Client expense: $70,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
Client expense: $70,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
Client expense: $70,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
Client expense: $70,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $216,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA), White House Office
Client expense: $236,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA), White House Office
Client expense: $6,230,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), President of the U.S., SENATE, U.S. Trade Representative (USTR)
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $6,310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $870,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $6,220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE